Table 2.

Assessment of LQT-TRAIL-NO@Nanogel toxicity

Treatment	AST (U/L)	ALT (U/L)	BUN (mg/dL)	CREA (mg/dL)	ALP (U/L)	γ-GT (U/L)	MetHb (%)
Control	95.8±19.2	32.0±3.6	24.3±3.4	0.14±0.03	360.2±65.2	0.3±0.4	1.05±0.06
LQT-TRAIL-NO @Nanogel	96.9±21.2	49.4±14.6	22.0±2.8	0.17±0.04	242.4±21.1	0.3±0.3	1.03±0.05

Serum was collected from healthy FVB mice at 24 hours after intravenously injection of LQT-TRAIL-NO@Nanogel to evaluate hepatic and renal toxicity markers (n=4).

Data are presented as the mean±SEM.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CREA, creatinine; MetHb, Methemoglobin; γ-GT, γ-glutamyltransferase.